All In Biotech

Drug Trial Radar · NCT03414645

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

Randomized Multicenter Double-Masked Placebo-Controlled Parallel Phase I/II Study to Determine the Safety and Exploratory Efficacy of Topical Fibrinogen Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs Host Disease

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

64

Actual

Start

May 1, 2018

Primary completion

Dec 12, 2019

Study completion Feb 20, 2020

Sponsor

Lead sponsor
Cambium Bio LimitedIndustry
Sponsor type
Industry
Collaborators
Massachusetts Eye and Ear Infirmary; Oregon Health and Science University; University of Michigan; Duke University; Stanford University; University of Minnesota
First posted
Jan 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1/2 study is to compare the safety and tolerability of four times a day (QID) dosing of a non-preserved topical ocular drop formulation of 10 vol/vol % and 30 vol/vol % of FD hPL to vehicle control eye drops in patients with Dry Eye Disease (DED) secondary to Graft vs. Host Disease (GvHD).

Conditions

  • Dry Eye
  • Graft-versus-host-disease
  • Ocular Discomfort

Interventions

  • CAM-101 10%Biological

    fibrinogen-depleted human platelet lysate

  • Vehicle ControlBiological

    PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop

  • CAM-101 30%Biological

    fibrinogen-depleted human platelet lysate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Ocular Treatment-related Adverse Events as Assessed by CTCAE v4.0Time frame: 42 Days
  2. Number of Participants With Systemic Treatment-related Adverse Events as Assessed by CTCAE v4.0Time frame: 42 Days
  3. Number of Participants With Treatment-related Adverse Events as Assessed Change From Normal to Abnormal With Clinical Significance in Any Ocular ExaminationTime frame: 42 Days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Byers Eye Institute of Stanford University

    Palo Alto, California

  • Massachusetts Eye and Ear Infirmary

    Boston, Massachusetts

  • University of Michigan - Kellogg Clinical Research Center

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Duke University Eye Center

    Durham, North Carolina

  • Oregon Health Sciences University - Casey Eye Institute

    Portland, Oregon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.